Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | FOS | P01100 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 8/20 | 0.41 |
| ▸ | PPARD | Q03181 | 7/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7187185 | 0.93 | FOS (0.43) | THRATHRBFOSJUNABCB1 | |
| SCHEMBL7191822 | 0.92 | PPARG (0.46) | THRATHRBFOSJUNABCB1 | |
| SCHEMBL7196306 | 0.85 | PPARG (0.47) | FOSJUNABCB1PPARGPPARD | |
| SCHEMBL7194767 | 0.84 | NPC1 (0.41) | ABCB1PPARGPPARDPPARAGPR88 | |
| SCHEMBL7194920 | 0.84 | ALOX5 (0.42) | THRATHRBABCB1MTNR1AMTNR1B | |
| SCHEMBL7188261 | 0.84 | PPARG (0.37) | ABCB1PPARGPPARDPPARAMTNR1A | |
| SCHEMBL7193285 | 0.83 | PPARG (0.45) | PPARGPPARDPPARA | |
| SCHEMBL7193141 | 0.82 | PPARG (0.39) | PPARGPPARDPPARAGPR88PTGES | |
| SCHEMBL7195716 | 0.82 | PPARG (0.37) | PPARGPPARDPPARAMTNR1AMTNR1B | |
| SCHEMBL7190696 | 0.82 | FOS (0.46) | THRBFOSJUNABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | STATENS SERUM INSTITUTE (DK) | 2003-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | AKR1C3, AKR1C1, AKR1A1 | THRA 2660/4885THRB 2309/4885FOS 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.